UNSPSC 51151507: Ambenonium

This classification denotes an acetylcholinesterase inhibitor with the molecular formula C28H42Cl2N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L16PUN799N, chemically known as benzenemethanaminium, n,n-((1,2-dioxo-1,2-ethanediyl)bis(imino-2,1-ethanediyl))bis(2-chloro-n,n-diethyl- but generally known as ambenonium, which bears US NIH Compound Identifier 2131. Ambenonium most often comes in base, chloride, and dichloride forms.

UNSPSC 51151507 Ambenonium is a Commodity code that, based on recent state and local solicitation activity, encompasses pharmaceutical products and related health interventions procured by public health authorities and state agencies. The recent opportunities show state and local governments buying naloxone (an opioid antagonist) and drug deactivation systems for community health initiatives, as well as exploring direct-to-manufacturer prescription fulfillment models to manage pharmacy benefit costs. The issuing bodies include county health departments and state health and human services commissions. Seminole County, Florida has solicited naloxone and drug deactivation systems through competitive bidding; the Texas Health and Human Services Commission has issued an RFI to assess vendor capabilities for direct pharmaceutical contracting outside traditional pharmacy benefit manager and group purchasing organization channels. Both procurements reflect growing state and local interest in alternative supply and delivery models for pharmaceutical products.

Recent activity concentrates in Florida and Texas. Seminole County's IFB 60459723LAS, posted June 30, 2026, sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission's RFI HHS0017013, posted April 3, 2026, solicited vendor information on implementing a direct-to-manufacturer prescription program that would establish direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers. The code shows limited recent posting volume, and the two opportunities reflect distinct procurement approaches—Seminole County's transactional purchase of emergency-response pharmaceuticals versus Texas HHS's market intelligence gathering on alternative pharmacy contracting models—suggesting the code may serve multiple, disparate public health functions rather than a single coherent commodity category.